(Q43191747)

15 November 2017

title

Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats (English)

1 reference

15 November 2017

1

Zofia Rogóz

1 reference

15 November 2017

publication date

1 November 2009

1 reference

15 November 2017

published in

Pharmacological Reports

1 reference

15 November 2017

volume

61

1 reference

15 November 2017

issue

6

1 reference

15 November 2017

page(s)

1173-1178

1 reference

Corticosterone influences forced swim-induced immobility

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Metyrapone displays antidepressant-like properties in preclinical paradigms.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

The corticosteroid receptor hypothesis of depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

ACTH, cortisol, and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone. IV. Influence of haloperidol (R 1625) and of chlorpromazine on the behaviour of rats in an unfamiliar "open field" situation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Are CRF receptor antagonists potential antidepressants?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Behavioural despair in rats: A new model sensitive to antidepressant treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970180-X

7 January 2021

10.1016/S1734-1140(09)70180-X

Identifiers

DOI

1 reference

15 November 2017

1 reference